Brian Ho

The sole sponsor, Huatai Financial Holdings (Hong Kong) Limited, and the underwriters on the global offering and listing of Shanghai Iluvatar CoreX Semiconductor Co., Ltd. (HKSE: 9903) on the Hong Kong Stock Exchange. Iluvatar CoreX is a leading player in China’s general-purpose GPU industry

Edding Group Company Limited, an integrated biopharmaceutical company, in connection with its merger with Genor Biopharma Holdings Limited, a Hong Kong-listed biopharmaceutical company under Chapter 18A, and the listing on the Main Board of HKEx. The deal represents the first ever reverse takeover relating to a Chapter 18A listed company. This transaction was named “Deals of the Year 2024” by China Business Law Journal and “M&A Deal of the Year 2025” by ALB China Awards

Carlyle-backed ADICON on its acquisition of Crown Bioscience

Centurium Capital, Temasek and True Light on the proposal to delist ANE (Cayman) Inc. from the Hong Kong Stock Exchange by way of a scheme of arrangement

MicroPort CardioFlow Medtech Corporation (HKSE: 2160) on its proposed merger with MicroPort Cardiac Rhythm Management Limited

Contemporary Amperex Technology Co., Limited (CATL) on its global offering and listing on the Hong Kong Stock Exchange. The IPO raised approximately HK$41 billion (US$5.3 billion) after the exercise of the over-allotment option. CATL is a global leader in new energy innovative technologies, primarily engaged in the research, development, production, and sales of EV and ESS batteries. This transaction was named “Best Equity Deal (APAC and Hong Kong)” and "Highly commended Best IPO (Hong Kong)" by FinanceAsia Achievement Awards 2025.

Duality Biotherapeutics (HKSE: 9606) on its global offering and listing on the Main Board of the Hong Kong Stock Exchange. The IPO raised approximately HK$1.64 billion prior to the exercise of the over-allotment option

PAG (as the offeror) on its proposed privatization of Shandong Fengxiang (HKSE: 9977) by way of merger by absorption

NIO Inc. (NYSE: NIO; HKSE: 9866; SGX: NIO) in connection with its HK$4,030.13 million offering of 136,800,000 class A ordinary shares. This transaction was named the “Most Innovative Deal (Hong Kong)” by FinanceAsia Achievement Awards 2025.

Skyworth Group (HKSE: 00751) on its HK$1,088.5 million share buyback by way of general offer

UBS AG, as the financial adviser to Guotai Junan, on the merger with Haitong Securities. This transaction was named “Deals of the Year 2024” by China Business Law Journal and “M&A Deal of the Year 2025” by ALB China Awards

The offeror on its proposed privatization of Vesync (HKSE: 2148)

A consortium of investors led by Starwood Capital Group, Sixth Street and SSW Partners, and which also includes QIA, Warburg Pincus, and the Founders of ESR Group (ESR), on their proposal to privatize ESR by way of scheme of arrangement from the Hong Kong Stock Exchange

Fangzhou Inc. (HKSE: 6086), the largest online chronic disease management platform in China in terms of average monthly active users in 2023, on the global offering and listing on The Stock Exchange of Hong Kong Limited on July 9, 2024

Celestial Link Limited, an investment vehicle ultimately controlled by PCCW Limited (HKSE: 0008), in its HK$280 million PIPE investment as a lead investor in the de-SPAC merger of HK Acquisition Corporation (a SPAC listed in Hong Kong under the stock code 7841) and Synagistics Pte. Ltd.

Morgan Stanley, as financial adviser, on:

• the proposed privatization of Hang Seng Bank by HSBC Holdings plc
• the mandatory unconditional cash offers for Lufax Holding by An Ke Technology and China Ping An Insurance

Super Hi International Holding Ltd. (HKSE: 9658; NASDAQ: HDL) on its initial public offering on the Nasdaq Global Market, making it the first high-profile company to list first in Hong Kong and then in the United States in recent years. This transaction was named “Best IPO – APAC & Hong Kong SAR” and “Most Innovative Deal - Hong Kong SAR” by FinanceAsia Achievement Awards 2024. This transaction was named “Best IPO – APAC & Hong Kong SAR” and “Most Innovative Deal - Hong Kong SAR” by FinanceAsia Achievement Awards 2024

J.P. Morgan, as financial adviser to L’Occitane Groupe S.A., in its privatisation of L’Occitane International S.A. (HKSE: 973). This transaction was named “Most Innovative Deal – APAC & Hong Kong SAR” by FinanceAsia Achievement Awards 2024 and “Deals of the Year 2024” by China Business Law Journal and “M&A Deal of the Year 2024” by IFLR

Independent Board Committee of Vinda International Holdings Limited (HKSE: 3331) in the voluntary conditional cash offer from Isola Castle Ltd. This transaction was named “Best M&A Deal - Hong Kong SAR” by FinanceAsia Achievement Awards 2024

Independent Board Committee of ENM Holdings Limited (HKSE:128) in the proposed scheme of arrangement and withdrawal of listing

iMotion Automotive Technology (Suzhou) Co., Ltd. (“iMotion”) (HKSE: 1274) on the initial public offering of H shares and listed on the Main Board of the Hong Kong Stock Exchange. As the first company specializing in autonomous driving listed on the Hong Kong Stock Exchange, iMotion is an autonomous driving solution provider with a focus on AD domain controllers

ZX Inc. (HKSE: 9890), a leading online game products publisher in China, on its global offering and listing on the Hong Kong Exchanges and Clearing Limited on September 28, 2023

NIO Inc. (NIO) (NYSE: NIO; HKSE: 9866; SGX: NIO) in its offering of US$500 million in aggregate principal amount of convertible senior notes due 2029 (2029 Notes) and US$500 million in aggregate principal amount of convertible senior notes due 2030 (2030 Notes). This transaction was named “Deals of the Year 2023” by China Business Law Journal and “Debt & Equity-linked Deal of the Year” by IFLR Asia-Pacific Awards 2024

ZG Group, a leading iron & steel e-commerce platform in China, on its business combination with Aquila Acquisition Corporation, a special purpose acquisition company. This is the first de-SPAC transaction in Hong Kong since the introduction of the SPAC listing regime in Hong Kong on 1 January 2022

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKSE: 6990) on its US$174 million global offering and listing on the The Stock Exchange of Hong Kong Limited on July 11, 2023. This transaction was named “Best IPO - Hong Kong SAR” by FinanceAsia Achievement Awards 2023

Power Heritage Group as the offeror on its privatization of Jiangnan Group Limited (HKSE: 1366)

SciClone Pharmaceuticals (HKSE: 6600) on its HK$780 million voluntary conditional buy-back cash offer

Link REIT (HKSE: 823) on its acquisition of a portfolio of assets in Singapore, including retail malls Jurong Point and Thomson Plaza, at a consideration of approximately S$2.16 billion (approximately $1.6 billion). This marks Link REIT’s first real estate acquisition in Singapore. This transaction was named “Best Property Deal - Singapore” by FinanceAsia Achievement Awards 2023

Skyworth Group Limited (HKSE: 00751) in its HK$380 million voluntary conditional cash offer to buy-back a maximum of 100 million shares at HK$3.80 per share, representing approximately 3.87% of Skyworth Group’s total issued share capital